Literature DB >> 29234257

Dual HER2 Blockade.

Christoph Thomssen1, Nagi S El Saghir2, Prudence A Francis3, Jacek Jassem4, Hope S Rugo5, Michael Untch6.   

Abstract

Entities:  

Year:  2017        PMID： 29234257      PMCID： PMC5704717          DOI： 10.1159/000484226

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN： 1661-3791            Impact factor:   2.860


× No keyword cloud information.
  8 in total

1.  Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.

Authors:  Sara M Tolaney; William T Barry; Chau T Dang; Denise A Yardley; Beverly Moy; P Kelly Marcom; Kathy S Albain; Hope S Rugo; Matthew Ellis; Iuliana Shapira; Antonio C Wolff; Lisa A Carey; Beth A Overmoyer; Ann H Partridge; Hao Guo; Clifford A Hudis; Ian E Krop; Harold J Burstein; Eric P Winer
Journal:  N Engl J Med       Date:  2015-01-08       Impact factor: 91.245

2.  De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.

Authors:  G Curigliano; H J Burstein; E P Winer; M Gnant; P Dubsky; S Loibl; M Colleoni; M M Regan; M Piccart-Gebhart; H-J Senn; B Thürlimann; F André; J Baselga; J Bergh; H Bonnefoi; S Y Brucker; F Cardoso; L Carey; E Ciruelos; J Cuzick; C Denkert; A Di Leo; B Ejlertsen; P Francis; V Galimberti; J Garber; B Gulluoglu; P Goodwin; N Harbeck; D F Hayes; C-S Huang; J Huober; K Hussein; J Jassem; Z Jiang; P Karlsson; M Morrow; R Orecchia; K C Osborne; O Pagani; A H Partridge; K Pritchard; J Ro; E J T Rutgers; F Sedlmayer; V Semiglazov; Z Shao; I Smith; M Toi; A Tutt; G Viale; T Watanabe; T J Whelan; B Xu
Journal:  Ann Oncol       Date:  2017-08-01       Impact factor: 32.976

3.  Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Arlene Chan; Suzette Delaloge; Frankie A Holmes; Beverly Moy; Hiroji Iwata; Vernon J Harvey; Nicholas J Robert; Tajana Silovski; Erhan Gokmen; Gunter von Minckwitz; Bent Ejlertsen; Stephen K L Chia; Janine Mansi; Carlos H Barrios; Michael Gnant; Marc Buyse; Ira Gore; John Smith; Graydon Harker; Norikazu Masuda; Katarina Petrakova; Angel Guerrero Zotano; Nicholas Iannotti; Gladys Rodriguez; Pierfrancesco Tassone; Alvin Wong; Richard Bryce; Yining Ye; Bin Yao; Miguel Martin
Journal:  Lancet Oncol       Date:  2016-02-10       Impact factor: 41.316

4.  5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.

Authors:  Luca Gianni; Tadeusz Pienkowski; Young-Hyuck Im; Ling-Ming Tseng; Mei-Ching Liu; Ana Lluch; Elżbieta Starosławska; Juan de la Haba-Rodriguez; Seock-Ah Im; Jose Luiz Pedrini; Brigitte Poirier; Paolo Morandi; Vladimir Semiglazov; Vichien Srimuninnimit; Giulia Valeria Bianchi; Domenico Magazzù; Virginia McNally; Hannah Douthwaite; Graham Ross; Pinuccia Valagussa
Journal:  Lancet Oncol       Date:  2016-05-11       Impact factor: 41.316

5.  Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.

Authors:  Gunter von Minckwitz; Marion Procter; Evandro de Azambuja; Dimitrios Zardavas; Mark Benyunes; Giuseppe Viale; Thomas Suter; Amal Arahmani; Nathalie Rouchet; Emma Clark; Adam Knott; Istvan Lang; Christelle Levy; Denise A Yardley; Jose Bines; Richard D Gelber; Martine Piccart; Jose Baselga
Journal:  N Engl J Med       Date:  2017-06-05       Impact factor: 91.245

6.  Research needs in breast cancer.

Authors:  F Cardoso; N Harbeck; C H Barrios; J Bergh; J Cortés; N El Saghir; P A Francis; C A Hudis; S Ohno; A H Partridge; G W Sledge; I E Smith; K A Gelmon
Journal:  Ann Oncol       Date:  2017-02-01       Impact factor: 32.976

7.  Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

Authors:  José Baselga; Ian Bradbury; Holger Eidtmann; Serena Di Cosimo; Evandro de Azambuja; Claudia Aura; Henry Gómez; Phuong Dinh; Karine Fauria; Veerle Van Dooren; Gursel Aktan; Aron Goldhirsch; Tsai-Wang Chang; Zsolt Horváth; Maria Coccia-Portugal; Julien Domont; Ling-Min Tseng; Georg Kunz; Joo Hyuk Sohn; Vladimir Semiglazov; Guillermo Lerzo; Marketa Palacova; Volodymyr Probachai; Lajos Pusztai; Michael Untch; Richard D Gelber; Martine Piccart-Gebhart
Journal:  Lancet       Date:  2012-01-17       Impact factor: 79.321

8.  Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial.

Authors:  Martine Piccart-Gebhart; Eileen Holmes; José Baselga; Evandro de Azambuja; Amylou C Dueck; Giuseppe Viale; Jo Anne Zujewski; Aron Goldhirsch; Alison Armour; Kathleen I Pritchard; Ann E McCullough; Stella Dolci; Eleanor McFadden; Andrew P Holmes; Liu Tonghua; Holger Eidtmann; Phuong Dinh; Serena Di Cosimo; Nadia Harbeck; Sergei Tjulandin; Young-Hyuck Im; Chiun-Sheng Huang; Véronique Diéras; David W Hillman; Antonio C Wolff; Christian Jackisch; Istvan Lang; Michael Untch; Ian Smith; Frances Boyle; Binghe Xu; Henry Gomez; Thomas Suter; Richard D Gelber; Edith A Perez
Journal:  J Clin Oncol       Date:  2015-11-23       Impact factor: 44.544
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.